About ABL
ABL is a Healthcare company based in Rockville (United States) founded in 1961, and was acquired by Oxford BioMedica in September 2023. Contract research and manufacturing for biologics and vaccines are provided. It operates on a Professional Services and Direct-to-Consumer (D2C) model. The company has 15 employees. Its Indian entity Abl Biosciences Private Limited reported revenue of ₹9.39 Cr. ABL offers products and services including Biomanufacturing, ELISA Kits, and Virus Manufacturing. Its focus areas include Biotechnology and Biomanufacturing. Its competitors include KBI Biopharma, Aldevron and Omnia Biologics; 2 of its 3 listed competitors have raised funding.
Company details
ABL, Inc. is involved in the development and manufacturing of vaccines and biotherapeutics. Services are provided in biomanufacturing, virus production, process development, and aseptic fill-finish. Solutions are offered for gene therapies, oncolytic vectors, immunotherapies, and viral vaccines. The company operates in the biotechnology sector, supporting preclinical and clinical development stages. Testing capabilities are also extended through biologics and quality control services. Partnerships with government entities are maintained to advance therapeutic solutions.
- Headquarters Rockville, United States
- Employees 15
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website ablinc.com
- Social LinkedIn Facebook
- Acquired by BioQual (Feb 2014)
- Legal Name Abl, Inc.
- Date of Incorporation 23 Aug, 2012
- Jurisdiction Hyderabad, Telangana, India
- Indian entity revenue₹9.39 Cr
FY 2025 · -26% YoY
- Indian entity net profit₹1.55 Cr
FY 2025 · 16% margin
- Indian entity EBITDA₹3.47 Cr
FY 2025 · 37% margin
- InvestorsOXB
& 1 more
- Employee Count15
- Acquired by
Associated legal entities of ABL
ABL operates through Abl Biosciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Abl Biosciences Private Limited CIN U01403TG2012PTC082635 | Active | 23 Aug 2012 | Hyderabad, Telangana | ₹9.4 Cr | 15 | 2 | View details |
Products & Services of ABL
ABL offers a comprehensive portfolio of products and services, including Biomanufacturing, ELISA Kits, and Virus Manufacturing.
Biomanufacturing services are provided for vaccine development.
ELISA kits are offered for research purposes.
Virus manufacturing is conducted for therapeutic applications.
Investors in ABL
ABL has secured backing from 2 investors. Prominent investors backing the company include OXB and BioQual.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Contract research on infectious disease models is conducted. | 1981 | bioqual.com | Rockville, United States | |
Gene therapies for multiple diseases are developed via lentiviral systems. | 1995 | oxb.com | Oxford, United Kingdom |
Investor details for ABL
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Abl Biosciences Private Limited (ABL)
Abl Biosciences Private Limited is the primary company behind ABL. The board of Abl Biosciences Private Limited currently have 2 directors; the longest-serving is Veeraiah Edara, appointed in 2012.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Veeraiah Edara DIN 01920686 | Director | 23 Aug 2012 | 14 yrs 2 mo | Abl Biosciences Private Limited |
| Venkata Prasanna Lakshmi Edara DIN 03608984 | Director | 23 Aug 2012 | 14 yrs 2 mo | Abl Biosciences Private Limited |
People of ABL
28 people are tracked at ABL (9 in leadership, 19 in team); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Yulia Lebedeva | Human Resources Director | Leadership |
Timothy Fouts | VP, Innovation & Translation | Leadership |
N-Neka Smith | VP, Quality Operations | Leadership |
Stéphanie Colloud | GM & COO, ABL Europe | Leadership |
Thierry Van Nieuwenhove | CEO | Leadership |
Yulia Sayegh | Director of Human Resources | Leadership |
Isabelle Pelletier | Head Of Upstream Process Development | Leadership |
Thomas Montague | Director Of Quality Assurance | Leadership |
Wah Cheung | Director Of Quality Assurance | Leadership |
Roshan B. | Manager, Fill Finish | Team |
Yansong Ni | Staff Scientist | Team |
Rose Marcheso-Hansen | Manager, Regional Sales | Team |
Kathleen Reed | Senior Research Specialist | Team |
Poorni Adikaram | Staff Scientist | Team |
Katelyn Sibiski | Quality Assurance Manager | Team |
Michael Roylance | QA Validations Manager | Team |
Carey O'Reilly | QA Specialist II | Team |
Shao Deng | Accounting Manager | Team |
Kathleen Drachbar | Quality Assurance Manager - Goverment Services And Supplier Quality | Team |
Thanhdao Nguyen | Senior Scientist | Team |
8 more people are available in the full profile.
Complete people profiles for ABL
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of ABL
Figures of Abl Biosciences Private Limited, the primary company behind ABL, for FY 2025. Revenue was ₹9.39 Cr (-26% year on year). Net profit was ₹1.55 Cr (16% margin). EBITDA was ₹3.47 Cr (37% margin). Revenue has grown at a compounded annual rate of 0% over three years and +20% over five years.
- ₹9.39 CrRevenue · FY 2025 · -26% YoY
- ₹1.55 CrNet profit · 16% margin
- ₹3.47 CrEBITDA · 37% margin
- ₹2.25 CrPaid-up capital
- 15Employees (provident fund records)
- 0%Revenue CAGR, 3 years
- +20%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Abl Biosciences Private Limited are on its company page.
Detailed financial statements for ABL
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of ABL
3 dated milestones of ABL across 62 years, from founding to its latest funding, stage changes and deals.
- Founded ABL is founded.
- Exit Acquired by BioQual.
- Exit Acquired by Oxford BioMedica.
Competitors of ABL
ABL has 3 listed competitors in our database, 2 of them funded. They include KBI Biopharma, Aldevron and Omnia Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kbibiopharma.com | 1996 | Durham, United States | $17M | 1,243 | Provider of protein formulation, process & cell line development, and cGMP services | |
| aldevron.com | 1998 | Fargo, United States | 747 | Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications | ||
| omniabio.com | 2001 | Rockville, United States | $25.4M | Process development and manufacturing services for biologics are provided. |
Detailed competitors of ABL
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ABL
The website of ABL (ablinc.com) receives about 9.7K visits a month and ranks #3,625,337 among all websites worldwide, #4,667 in Biotechnology and Pharmaceuticals.
- Monthly visits9.7K
▲ 87.7% vs previous month
- Unique visitors2.1K
per month
- Global rank#3,625,337
among all websites
- Category rank#4,667
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.8
- Average visit34 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with ABL. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biosciencelabs.com | 100% | View details | |||
| meridianbioscience.com | 60% | 31.9K | #999,696 | View details | |
prize4life.org | prize4life.org | 59% | – | ||
| darkdaily.com | 58% | View details | |||
| flucamp.com | 57% | #490,754 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as ABL (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abl
Complete news archive for ABL
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ABL
ABL was founded in 1961.
ABL is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
ABL has 15 employees.
The primary company behind ABL, Abl Biosciences Private Limited, reported revenue of ₹9.39 Cr for FY 2025, down 26% year on year.
ABL, Inc. is involved in the development and manufacturing of vaccines and biotherapeutics. Services are provided in biomanufacturing, virus production, process development, and aseptic fill-finish. Solutions are offered for gene therapies, oncolytic vectors, immunotherapies, and viral vaccines. The company operates in the biotechnology sector, supporting preclinical and clinical development stages. Testing capabilities are also extended through biologics and quality control services. Partnerships with government entities are maintained to advance therapeutic solutions.
ABL's top competitors include KBI Biopharma, Aldevron and Omnia Biologics.
ABL offers Biomanufacturing, ELISA Kits, and Virus Manufacturing.
ABL operates through Abl Biosciences Private Limited.
Yes. ABL was acquired by BioQual in February 2014.
The legal entities of ABL currently have 2 directors, including Veeraiah Edara, Venkata Prasanna Lakshmi Edara.

